PMID- 37580206
OWN - NLM
STAT- Publisher
LR  - 20230814
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2023 Aug 3
TI  - HDL abnormalities in type 2 diabetes: Clinical implications.
PG  - 117213
LID - S0021-9150(23)05127-4 [pii]
LID - 10.1016/j.atherosclerosis.2023.117213 [doi]
AB  - Atherosclerotic cardiovascular disease (ASCVD) represents the primary cause of 
      mortality among patients with Type 2 Diabetes Mellitus (T2DM). In this 
      population, High-Density Lipoprotein (HDL) particles exhibit abnormalities in 
      number, composition, and function, culminating in diminished anti-atherosclerotic 
      capabilities despite normal HDL cholesterol (HDL-C) concentrations. Hyperglycemic 
      conditions contribute to these alterations in HDL kinetics, composition, and 
      function, causing T2DM patients' HDL particles to exhibit decreased 
      concentrations of diverse lipid species and proteins. Treatment of hyperglycemia 
      has the potential to correct abnormal HDL particle attributes in T2DM; however, 
      pharmacological interventions, including metformin and thiazolidinediones, yield 
      inconsistent outcomes with respect to HDL-C concentrations and functionality. 
      Despite numerous attempts with diverse drugs, pharmacologically augmenting HDL-C 
      levels has not resulted in clinical benefits in mitigating ASCVD risk. In 
      contrast, reducing Low Density Lipoprotein cholesterol (LDL-C) via statins and 
      ezetimibe has demonstrated significant efficacy in curtailing CVD risk among T2DM 
      individuals. Promising results have been observed in animal models and 
      early-phase trials utilizing recombinant HDL and Lecitin Cholesterol Acyl 
      Transferase (LCAT) -enhancing agents, but the evaluation of their efficacy and 
      safety in large-scale clinical trials is ongoing. While aberrant HDL metabolism 
      constitutes a prevalent aspect of dyslipidemia in T2DM, HDL cholesterol 
      concentrations and composition no longer offer valuable insights for informing 
      therapeutic decisions. Nevertheless, HDL metabolism remains a critical research 
      area in T2DM, necessitating further investigation to elucidate the role of HDL 
      particles in the development of diabetes-associated complications.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Martagon, Alexandro J
AU  - Martagon AJ
AD  - Unidad de Investigacion de Enfermedades Metabolicas Instituto Nacional de 
      Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Institute for 
      Obesity Research, Tecnologico de Monterrey, Mexico City, Mexico; Tecnologico de 
      Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.
FAU - Zubiran, Rafael
AU  - Zubiran R
AD  - Unidad de Investigacion de Enfermedades Metabolicas Instituto Nacional de 
      Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Gonzalez-Arellanes, Rogelio
AU  - Gonzalez-Arellanes R
AD  - Institute for Obesity Research, Tecnologico de Monterrey, Mexico City, Mexico.
FAU - Praget-Bracamontes, Samantha
AU  - Praget-Bracamontes S
AD  - Unidad de Investigacion de Enfermedades Metabolicas Instituto Nacional de 
      Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Rivera-Alcantara, J Adrian
AU  - Rivera-Alcantara JA
AD  - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico 
      City, Mexico.
FAU - Aguilar-Salinas, Carlos A
AU  - Aguilar-Salinas CA
AD  - Unidad de Investigacion de Enfermedades Metabolicas Instituto Nacional de 
      Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Direccion de 
      Investigacion, Instituto Nacional de Ciencias Medicas y Nutricion Salvador 
      Zubiran, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y 
      Ciencias de la Salud, Mexico City, Mexico; Gilbert and Rose-Marie Chagoury School 
      of Medicine, Lebanese American University, Beirut, Lebanon. Electronic address: 
      carlos.aguilars@incmnsz.mx.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230803
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
SB  - IM
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Cardiovascular disease
OT  - Cholesterol efflux
OT  - HDL
OT  - Reverse cholesterol transport
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper
EDAT- 2023/08/15 00:42
MHDA- 2023/08/15 00:42
CRDT- 2023/08/14 21:55
PHST- 2023/04/30 00:00 [received]
PHST- 2023/07/30 00:00 [revised]
PHST- 2023/08/02 00:00 [accepted]
PHST- 2023/08/15 00:42 [medline]
PHST- 2023/08/15 00:42 [pubmed]
PHST- 2023/08/14 21:55 [entrez]
AID - S0021-9150(23)05127-4 [pii]
AID - 10.1016/j.atherosclerosis.2023.117213 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2023 Aug 3:117213. doi: 10.1016/j.atherosclerosis.2023.117213.